Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Cancer registration statistics, England; 2014. Newport, South Wales, UK. Available at: https://www.ons.gov.uk/
   Google Scholar
• American Cancer Society. Lung cancer [Internet]. 2017. Atlanta, GA, USA. Available at: https://www.cancer.org/cancer/lung-cancer.html
   Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
   PubMed Web of Science ®Google Scholar
• Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629-40
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7
   PubMed Web of Science ®Google Scholar
• Eberhardt WE, De RD, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015;26:1573-88
   PubMed Web of Science ®Google Scholar
• NHS England Cancer Drugs Fund Team Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund). A new deal for patients, taxpayers and industry; 2016. London, UK. Available at: https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer. Technology appraisal guidance [TA416]; 2014. London, UK. Available at: https://www.nice.org.uk/guidance/ta416
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [PMG9]; 2013. Available at: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case
   Google Scholar
• National Institute for Health and Care Excellence. Appraising life-extending, end of life treatments; 2009. London, UK. Available at: https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2
   Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health 2012;15:812-20
   PubMed Web of Science ®Google Scholar
• Yang JCH, Ramalingam SS, Janne PA, et al. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016;11(4Suppl):S152-3
   Web of Science ®Google Scholar
• Goss G, Tsai CM, Shepherd A, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016;17:1643-52
   PubMed Web of Science ®Google Scholar
• Yang JC, Ahn MJ, Kim DW, at al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component. J Clin Oncol 2017;35:1288-96
   PubMed Web of Science ®Google Scholar
• Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015;16:990-8
   PubMed Web of Science ®Google Scholar
• Andersohn F, Mann H, Mitsudomi T, et al. Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI. Poster presented at: European Society for Medical Oncology; Oct 7–11, 2016; Copenhagen, Denmark. Ann Oncol 2016;27(Suppl 6):1246P
   Web of Science ®Google Scholar
• Latimer M. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data; 2011. Available at: http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf
   Google Scholar
• Common Terminology Criteria for Adverse Events. Version 4.03. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, June 14, 2010
   Google Scholar
• British National Formulary. British National Formulary (Medicines Complete Online); 2015. British Medical Association and Royal Pharmaceutical Society, London. Available at: http://www.bnforg/
   Google Scholar
• National Health Service. NHS reference costs guidance 2014 to 2015; 2015. London, UK. Available at: https://www.gov.uk/government/collections/nhs-reference-costs
   Google Scholar
• Personal Social Services Research Unit. Unit costs of health and social care 2015; 2015. London, UK. Available at: http://www.pssru.ac.uk/project-pages/unit-costs/2015/
   Google Scholar
• Brown T, Pilkington G, Bagust A, et al. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess 2013;17:1-278
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. Technology appraisal guidance [TA374]; 2015. London, UK. Available at: http://www.nice.org.uk/guidance/TA374
   Google Scholar
• National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. Clinical guideline [CG121]; 2011. London, UK. Available at: http://www.nice.org.uk/guidance/cg121
   Google Scholar
• van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. Early access to medicines scheme scientific opinion - Public Assessment Report Osimertinib; 2015. London, UK. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/482863/Osimertinib__AZD9291__EAMS_Public_Assessment_Report.pdf
   Google Scholar
• European Medicines Agency. Tagrisso; 2016. London, UK. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004124/human_med_001961.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Blackhall F, Kim DW, Besse B, et al. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol 2014;9:1625-33
   PubMed Web of Science ®Google Scholar
• Soria JC, Kim SW, Wu YL, et al. Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): final overall survival (OS) analysis. Presented at: European Society for Medical Oncology; Oct 7–11, 2016; Copenhagen, Denmark. Available at: http://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Gefitinib-chemotherapy-vs-chemotherapy-in-EGFR-mutation-positive-NSCLC-after-progression-on-1st-line-gefitinib-IMPRESS-study-Final-overall-survival-OS-analysis
   Google Scholar